Alzinova presents its company and projects to investors and international pharmaceutical companies
Alzinova AB (publ) ("Alzinova" or the "Company") will present the Company at both Swedish and international investor meetings during the autumn. The Company will participate in one of the major biotech conferences in Europe, BIO-Europe, which is a forum for partner meetings where the Company will present the vaccine candidate ALZ-101 and the antibody ALZ-201 to potential partners.
Alzinova's strategy, to develop an effective and safe treatment for Alzheimer's disease that targets the toxic forms of amyloid beta, the oligomers, has been gaining interest. Preclinical data has documented "best in class" potential and results from other actors in the field strengthen the case for the Company's strategy. The Company will increase its participation in partnering meetings, with the goal of establishing global partnerships.
International partnering conferences:
BIO-Europe, October 24-26
BIO-Europe, the pharmaceutical industry's largest partnering meeting in Europe, will be held this year in Leipzig from 24-26 October. Participants typically number in the tens of thousands of delegates from around the world, who meet to discuss licensing deals and research collaborations. Alzinova's Chief Executive Officer, Kristina Torfgård and Chief Scientific Officer, Anders Sandberg will meet partners from their global network in the pharmaceutical industry and establish new contacts with a focus on presenting and marketing the Company's pharmaceutical projects. Read more here: https://informaconnect.com/bioeurope/
Clinical Trials on Alzheimer's Disease conference (CTAD), November 29 - December 2
CTAD is one of the three most important Alzheimer's conferences and will be held from November 29 to December 2, 2022, in San Francisco. The conference is focused on therapeutic development for the treatment of Alzheimer's disease, bringing together prominent leaders within research, industry and academia to form partnerships to accelerate the development of effective treatments to tackle the disease. In conjunction with the conference, Alzinova's CSO Anders Sandberg will present a scientific poster on the Company's antibody candidate ALZ-201. Read more about the event here: https://www.ctad-alzheimer.com/
For investors:
Redeye Theme: Neurology, October 12
CEO Kristina Torfgård will present the Company at the Redeye event "Redeye Theme: Neurology" in Stockholm on October 12. Read more: https://www.redeye.se/events/847068/redeye-theme-neurology
Mangold Insight Investor Day - Life Science, November 16
Azinova CEO Kristina Torfgård will present the Company at Mangold Insight's Investor Day - Life Science theme on November 16. For more information: https://mangold.se/
Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.
For more information, please contact:
Kristina Torfgård, CEO
Tel. +46 708 46 79 75
E-mail: kristina.torfgard@alzinova.com
About Alzinova AB
Alzinova AB is a Swedish clinical-stage biopharma company developing treatments for Alzheimer’s disease by specifically targeting neurotoxic amyloid beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that has unique ability and precision to target the toxic amyloid-beta oligomers involved in the onset and progression of the disease. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The Company’s Certified Advisor on Nasdaq First North Growth Market is Corpura. For more information about Alzinova, please visit: www.alzinova.com